U.S. Physical Therapy (USPH) has wrapped up FY 2025 with fourth quarter revenue of US$201.0 million and basic EPS of US$0.27, alongside trailing twelve month EPS of US$2.61 on revenue of US$773.3 million. Over the past six reported quarters in the dataset, revenue has moved from US$166.3 million in Q3 2024 to US$201.0 million in Q4 2025, while quarterly EPS ranged from US$0.27 to US$0.80, with full year earnings growth of 42.8% and a net margin of 5.1% versus 4.2% a year earlier. That combination of higher earnings and firmer margins sets up a results season in which investors will be weighing how durable this profitability profile really is.

See our full analysis for U.S. Physical Therapy.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the prevailing market stories around U.S. Physical Therapy and where those narratives might need a rethink.

42.8% earnings growth vs 5 year decline

• Over the last 12 months, earnings grew 42.8%, while the five year average earnings trend shows a 2.6% decline per year, so you are looking at a strong recent upswing against a weaker longer term record.
• Consensus narrative highlights rising patient volumes and higher clinic visits per day as key supports for future earnings, yet the 2.6% annual earnings decline over five years and forecast earnings growth of 10.7% per year create a tension between recent strength and the longer history.
  • On the supportive side, trailing net income of US$39.6 million on US$773.3 million of revenue lines up with the idea that higher volumes are already working through the income statement.
  • On the cautious side, the longer term earnings decline and forecast revenue growth of 6.6% per year leave less room for error if patient volumes or reimbursement trends do not keep matching the optimistic narrative.

Analysts are weighing whether this sharp 42.8% rebound is the start of a new chapter or just a strong year in a bumpier record, and the consensus view tries to balance that mixed history against the current growth story. 📊 Read the what the Community is saying about U.S. Physical Therapy.

Margins at 5.1% under reimbursement pressure

• Trailing net profit margin sits at 5.1%, up from 4.2% a year earlier, and analysts in the dataset expect margins to reach about 5.7% in three years if things go according to plan.
• Bears focus on reimbursement cuts and rising labor costs, arguing that pressures like the cumulative US$25 million annualized Medicare headwind could keep margins tight even with the recent improvement.
  • The move from 4.2% to 5.1% margin alongside trailing revenue of US$773.3 million shows the company currently covering those pressures, but it also means every 1 percentage point of margin is worth roughly US$7.7 million of profit, so reimbursement or wage shifts matter a lot.
  • Forecast earnings growth of 10.7% per year and margin expansion to 5.7% assume that reimbursement and staffing conditions at least stay manageable, which is exactly what critics question when they point to clinician shortages and payer policy changes.

Some investors will see the 5.1% margin as proof the model is coping with reimbursement headwinds, while others will focus on how much profit could swing if payer or labor trends move against the company. 🐻 U.S. Physical Therapy Bear Case

High 30.5x P/E against DCF value gap

• The shares trade at a P/E of 30.5x compared with about 16x for peers and 23.6x for the wider healthcare industry, even though the current price of US$79.34 sits well below the DCF fair value of roughly US$159.55 and the analyst price target of US$105.33.
• Bullish investors argue that improving earnings and margins can justify this higher multiple, especially with analysts in the dataset expecting earnings of US$52.5 million and EPS of US$3.05 by about 2028, but the current premium P/E means a lot of that thesis is already reflected in the valuation.
  • At US$79.34, the stock is roughly 50.3% below the DCF fair value and about 32.8% below the implied upside in the dataset, which supports a more optimistic view on long term value if forecasts are met.
  • At the same time, sticking with a 30.5x P/E assumes the company can sustain earnings growth ahead of its 5 year trend and lift margins from 5.1% toward 5.7%, so any slowdown relative to the 10.7% earnings growth forecast would leave that premium harder to justify.

Supporters tend to focus on the gap to DCF fair value and the margin improvement, while skeptics look at the 30.5x P/E versus peers and ask how much of that future growth is already being paid for at today’s US$79.34 price. 🐂 U.S. Physical Therapy Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for U.S. Physical Therapy on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seen enough to form a first impression, or still on the fence? Take a moment to look through the numbers yourself and then weigh up the company’s 4 key rewards and 1 important warning sign.

See What Else Is Out There

For all the recent 42.8% earnings growth, U.S. Physical Therapy still carries a high 30.5x P/E on a bumpier five year earnings record and modest margins.

If that mix of premium valuation and a patchy earnings history feels a bit exposed, check out 80 resilient stocks with low risk scores to focus on companies where steadier fundamentals and lower risk scores may better match your comfort zone right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.